Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9345597 | 0.91 | MEN1 (0.50) | KMT2AMEN1ALOX15CYP2C19HSD17B10 | |
| SCHEMBL9343956 | 0.90 | TDP1 (0.40) | KMT2AMEN1ALOX15CYP2C19HSD17B10 | |
| SCHEMBL9348521 | 0.89 | MEN1 (0.39) | KMT2AMEN1ALOX15CYP2C19HSD17B10 | |
| SCHEMBL9345161 | 0.83 | MEN1 (0.56) | KMT2AMEN1ALOX15CYP2C19HSD17B10 | |
| SCHEMBL9348882 | 0.80 | MEN1 (0.41) | KMT2AMEN1ALOX15CYP2C19HSD17B10 | |
| SCHEMBL9348888 | 0.80 | MEN1 (0.41) | KMT2AMEN1ALOX15CYP2C19HSD17B10 | |
| SCHEMBL9344786 | 0.79 | MEN1 (0.43) | KMT2AMEN1ALOX15CYP2C19HSD17B10 | |
| SCHEMBL9344824 | 0.75 | PPARA (0.46) | MAPTPPARGPPARA | |
| SCHEMBL9343960 | 0.75 | MEN1 (0.52) | KMT2AMEN1ALOX15CYP2C19HSD17B10 | |
| SCHEMBL9344811 | 0.74 | MEN1 (0.69) | KMT2AMEN1ALOX15CYP2C19HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200163916-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) | 2020-05-28 | — | — | US | disclosed |
| US-5321016-A | Epliepsy, central nervous system disorders | SANDOZ PHARMACEUTICALS CORP. (US) | 1994-06-14 | — | — | US | disclosed |
| US-5162311-A | Treating epilepsy, psychiatric disorders | SANDOZ PHARMACEUTICALS CORP. (US) | 1992-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163916-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | NLN, CLN6, SLC1A2 | KMT2A 2257/4885MEN1 1615/4885ALOX15 1542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.